Literature DB >> 35805048

Metabolic Diseases and Risk of Head and Neck Cancer: A Cohort Study Analyzing Nationwide Population-Based Data.

Soo-Young Choi1, Hyeon-Kyoung Cheong2, Min-Kyeong Lee3, Jeong-Wook Kang1, Young-Chan Lee1, In-Hwan Oh4, Young-Gyu Eun1.   

Abstract

The aim of the study was to investigate the association between metabolic diseases and the risk of head and neck cancer (HNC) using nationwide population-based big data. This retrospective cohort study was conducted using the Korean National Health Insurance Service health checkup database. A total of 4,575,818 participants aged >40 years who received a health checkup in 2008 were enrolled, and we studied the incidence of HNC until 2019. We analyzed the risk of HNC according to the presence of metabolic diseases, such as obesity, dyslipidemia, hypertension, and diabetes. Although metabolic syndrome itself was not associated with HNC, each component of metabolic syndrome was associated with HNC. Underweight and diabetes were risk factors for HNC (HR: 1.694). High total cholesterol and high low-density lipoprotein cholesterol levels were factors that decreased the risk (HR 0.910 and 0.839). When we analyzed men and women separately, low total cholesterol level, low low-density lipoprotein cholesterol level, and hypertension were risk factors only in men. In addition, pre-obesity, obesity, and central obesity decreased the risk only in men. Each metabolic disease affects HNC in different ways. Underweight and diabetes increased the risk of HNC, whereas high total cholesterol and high low-density lipoprotein cholesterol levels decreased the risk of HNC.

Entities:  

Keywords:  diabetes; head and neck cancer; hypertension; metabolic syndrome; obesity

Year:  2022        PMID: 35805048      PMCID: PMC9265067          DOI: 10.3390/cancers14133277

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.575


1. Introduction

Worldwide, in 2017, more than 800,000 cases were newly diagnosed as head and neck cancers (HNC), and approximately 500,000 people died due to HNC [1]. HNC refers to cancers of the oral cavity, oropharynx, hypopharynx, and larynx [2], and these areas are associated with eating, talking, and breathing. For these reasons, the onset of HNC affects the quality of life more than that of other cancers, and the treatment method is difficult. Therefore, as with other cancers, it is important to identify and prevent the risk factors that cause HNC. Cigarettes, alcohol, and human papilloma virus are known to be the representative causes of HNC [3]. In recent years, many studies have reported the relationship between various cancers and metabolic diseases [4], Metabolic diseases usually include diabetes, hypertension, obesity, and dyslipidemia. The criteria for the clinical diagnosis of these have been proposed slightly differently by several expert groups [5,6,7,8,9], Diabetes and hypertension have been reported to be associated with various cancers [10,11,12]. Abdominal obesity is a risk factor for cancer and one of the factors that worsens the prognosis [13], and obesity increases the risk of breast cancer [14]. In addition, low high-density lipoprotein (HDL) cholesterol and high triglyceride (TG) levels are associated with lung cancer [15]. Chemoradiotherapy treatment, on the other hand, also exposes the patient to innumerable immune, nutritional and metabolic complications, often affecting the patient’s quality of life [16]. However, the association between the incidence of HNC and these metabolic diseases has not yet been clearly determined. Unlike other cancers, obesity has been reported to have a positive effect on the prognosis of HNC [17]. Since various cancers have different characteristics, in this study, we sought to investigate the association between metabolic diseases and the risk of HNC.

2. Materials and Methods

2.1. Study Population

The Korean government operates the public health insurance system through an organization called the Korean National Health Insurance Service (KNHIS), and for 97% of the entire population of Korea is compulsory to join [18]. The KNHIS recommends that adults aged > 40 years and employees aged > 20 years receive regular health checkups once every 1–2 years. The KNHIS has data such as demographics, diagnoses, and treatment records of individual diseases along with the health checkup data of subscribers. The health checkup data include information on height, weight, blood test results, and smoking and alcohol drinking status. We used this database from the KNHIS with official approval from the government. This study was conducted with patients aged > 40 years who underwent a health checkup from the KNHIS in 2008. Only those who had not previously been diagnosed with HNC were included, and we examined whether they had HNC from 2009 to 2019. In 2008, 6,093,826 people underwent routine health checkups. Of these, 1,502,198 were excluded as missing data. A total of 11,893 people were excluded because they were previously diagnosed with HNC. A total of 687 people who died or were diagnosed with HNC within 1 year were also excluded. Lastly, 3230 people who were diagnosed with cancer of the nasal cavity, middle ear, salivary gland, and nasopharynx were excluded. The flow diagram of the study population is demonstrated in Figure 1.
Figure 1

Flow diagram of the study population.

The study was approved by the Institutional Review Board (IRB) of Kyung Hee University Hospital on 8 November, 2019 and was performed in accordance with relevant guidelines and regulations (IRB No. 2019-11-002).

2.2. Definition of Variables

Metabolic syndrome was defined according to the International Diabetes Federation criteria [19]. According to this institution, for a person to be defined as having metabolic syndrome, they must have central obesity (waist circumference ≥ 90 cm for men and ≥80 cm for women), plus any two of the following four factors: elevated TG level (≥150 mg/dL or specific treatment for this lipid abnormality), reduced HDL cholesterol level (<40 mg/dL for men and <50 mg/dL for women), elevated blood pressure (systolic ≥ 130 mmHg or diastolic ≥ 85 mmHg or treatment of previously diagnosed hypertension), and elevated fasting plasma glucose level (≥100 mg/dL or previously diagnosed type 2 diabetes) [19]. Body mass index (BMI) was calculated by dividing the weight in kilograms by the square of height in meters (kg/m2). Based on BMI, the group was defined as underweight (<18.5 kg/m2), normal (18.5–22.9 kg/m2), pre-obese (23.0–24.9 kg/m2), and obese (≥25 kg/m2) [20]. For the lipid profile, when the total cholesterol (TC) level was ≥200 mg/dL, TG level was ≥150 mg/dL, and low-density lipoprotein (LDL) cholesterol level was ≥100 mg/dL, it was classified as high or abnormal, respectively. HDL cholesterol level was defined as low or abnormal when <40 mg/dL in men and <50 mg/dL in women [21]. Hypertension and diabetes were defined as previously diagnosed or treated using the KNHIS data, respectively. Standardized self-reported questionnaires were used to collect data on alcohol-drinking and smoking status at the time of enrollment. Alcohol drinking was classified as nondrinker, moderate drinker (ethanol, 0–30 g/day), and heavy drinker (ethanol, >30 g/day). Smoking status was classified as never smoker, ex-smoker, or current smoker. Age was defined as the age at which the patients were enrolled.

2.3. Statistical Analysis

Categorical variables such as sex, smoking and alcohol-drinking status, and past medical history are presented as frequency and percentage. The values of metabolic syndrome are presented as the mean and standard deviation. The differences between the HNC and control groups were analyzed using the chi-square and t-test. A Cox proportional hazard regression model was used to determine the relationship between metabolic syndrome and HNC. The hazard ratio and 95% confidence interval (CI) are presented. To determine the effect of sex, sex was stratified. SAS 9.4 (SAS Institute Inc., Cary, NC, USA) was used, and the significance of statistical tests was determined using the 0.05 level.

3. Results

3.1. Baseline Study Participant Characteristics

The demographic characteristics are summarized in Table 1. A total of 4,575,818 patients were analyzed, and 8749 patients were newly diagnosed with HNC during the analysis period. In the HNC group, 83.53% were men, which was higher than the 53.97% of the non-HNC group (p < 0.001). The mean age of the HNC group was 59.53 years, which was higher than that of the non-HNC group (53.96 years) (p < 0.001). Among the HNC patients, 5.86% were heavy drinkers, 48.01% were mild drinkers, and 46.13% were nondrinkers, whereas in the non-HNC group, 3.11% were heavy drinkers, 40.66% were mild drinkers, and 56.04% were nondrinkers (p < 0.001). The percentages of current smokers (34.82% vs. 20.26%) and ex-smokers (14.58% vs. 10.33%) were higher in the HNC group, while the percentage of never smokers was low (50.60% vs. 69.22%) (p < 0.001). The mean BMI was different in the two groups (23.70 kg/m2 in the HNC group and 23.98 kg/m2 in the non-HNC group) (p < 0.001). The mean waist circumferences were 83.78 cm in the HNC group and 81.68 cm in the non-HNC group (p < 0.001). Each mean of lipid profiles showed a significant difference in the two groups: the total cholesterol levels were 193.35 md/dL in the HNC group and 197.45 md/dL in the non-HNC group, the TG levels were 146.24 md/dL in the HNC group and 139.80 md/dL in the non-HNC group, the LDL cholesterol levels were 113.56 md/dL in the HNC group and 119.64 md/dL in the non-HNC group, the HDL cholesterol levels were 54.71 md/dL in the HNC group and 55.55 md/dL in the non-HNC group (p < 0.001, respectively) The proportions of hypertension were 58.37% in the HNC group and 48.89% in the non-HNC group (p < 0.001). The proportions of patients with diabetes were 17.02% in the HNC group and 11.75% in the non-HNC group (p < 0.001). In the HNC group, 29.03% met the criteria for metabolic syndrome, whereas in the non-HNC group, 26.16% met the criteria for metabolic syndrome (p < 0.001).
Table 1

Analysis of factors potentially associated with head and neck cancer.

ParameterWith HNC (n = 8749)Without HNC (n = 4,567,069)p Value
Sex, n (%) <0.001 *
Male7308 (83.53)2,469,600 (53,97)
Female1441 (16,47)2,097,469 (45,84)
Age, year59.53 ± 9.6953.96 ± 9.32<0.001 *
Alcohol drinking, n (%) <0.001 *
No4036 (46.13)2,564,134 (56.04)
Moderate4200 (48.01)1,860,466 (40.66)
Heavy513 (5.86)142,469 (3.11)
Smoking status, n (%) <0.001 *
Never smoker4427 (50.60)3,167,225 (69.22)0
Ex-smoker1276 (14.58)472,603 (10.33)
Current smoker3046 (34.82)927,241 (20.26)
Body mass index, kg/m223.70 ± 3.0023.98 ± 3.32<0.001 *
Waist circumference, cm83.78 ± 8.1681.68 ± 8.45<0.001 *
Total cholesterol, mg/dL193.35 ± 37.43197.45 ± 36.95<0.001 *
Triglyceride, mg/dL146.24 ± 98.10197.45 ± 36.95<0.001 *
LDL cholesterol, mg/dL113.56 ± 115.86119.64 ± 79.48<0.001 *
HDL cholesterol, mg/dL54.71 ± 31.4555.55 ± 31.890.0144 *
Hypertension, n (%) <0.001 *
No3642 (41.63)2,330,154 (50.92)
Yes5107 (58.37)2,236,915 (48.89)
Diabetes, n <0.001 *
No7260 (82.98)4,029,420 (88.06)
Yes1489 (17.02)537,649 (11.75)
Metabolic syndrome, n (%) <0.001 *
No6209 (70.97)3,372,434 (73.84)
Yes5540 (29.03)1,194,635 (26.16)

Values are mean ± standard deviation (SD) or % ± SD. * Significant at p < 0.05.

3.2. Impact of Each Factor on the Risk of HNC

Each factor was subdivided, and the effect of each factor on the risk of HNC was analyzed. When age was subdivided into 40 s to 80 s, the risk of HNC increased with increasing age. The hazard ratios of 40 s, 50 s, 60 s, 70 s, and 80 s were 1.982 (95% CI, 1.862–2.110), 3.000 (95% CI, 2.812–3.201), 3.736 (95% CI, 3.477–4.016), and 5.276 (95% CI, 4.430–6.283), respectively. Multivariable analysis was adjusted for factors including age and sex. Of 8749 patients with HNC, 2540 met the criteria for metabolic syndrome, and 6209 did not, and metabolic syndrome did not affect the adjusted hazard ratio (aHR) for the development of HNC. The aHR of HNC in heavy drinkers (1.498 [95% CI, 1.363–1.646]) was significantly higher than that in moderate drinkers (1.079 (95% CI, 1.030–1.131)) and nondrinkers. In the case of smoking status, the aHR of current smokers (1.668 (95% CI, 1.586–1.754)) was much higher than that of ex-smokers (1.668 (95% CI, 1.586–1.754)). The underweight group (BMI < 18.5 kg/m2) was a notable risk factor for HNC (aHR, 1.694 (95% CI, 1.505–1.906)). Inversely, the pre-obese (23.0–24.9 kg/m2) and obese (≥25 kg/m2) groups had lower aHRs of 0.838 (95% CI, 0.794–0.883) and 0.804 (95% CI, 0.765–0.846), respectively. Similarly, the aHR decreased when patients had central obesity (0.943 (95% CI, 0.879–0.992)). High TC and high LDL cholesterol levels decreased the aHR to 0.910 (95% CI, 0.871–0.949) and 0.839 (95% CI, 0.803–0.876), respectively. However, the TG and HDL cholesterol levels were not risk factors for HNC. When patients had diabetes, the aHR increased (1.181 (95% CI, 1.116–1.249)). Hypertension did not influence the incidence of HNC (Table 2).
Table 2

Hazard ratio of head and neck cancer risk according to each factor.

Parameter n HNC (Adjusted for Age and Sex)
p ValueHR (95% CI)
Alcohol drinking, n
No4036 1 (reference)
Moderate42000.00131.079 (1.030–1.131)
Heavy513<0.0011.498 (1.363–1.646)
Smoking status, n
Never smoker4427 1 (reference)
Ex-smoker1276<0.0011.185 (1.110–1.265)
Current smoker3046<0.0011.668 (1.586–1.754)
BMI, kg/m2
<18.5303<0.0011.694 (1.505–1.906)
18.5–22.93250 1 (reference)
23–24.92344<0.0010.838 (0.794–0.883)
≥252852<0.0010.804 (0.765–0.846)
Central obesity
No6691 1 (reference)
Yes20580.02180.943 (0.897–0.992)
Total cholesterol
Low5198 1 (reference)
High3551<0.0010.910 (0.871–0.949)
LDL cholesterol
Low3257 1 (reference)
High5492<0.0010.839 (0.803–0.876)
TG
Low5657 1 (reference)
High30920.6491.010 (0.967–1.056)
HDL cholesterol
Low71580.75731.009 (0.955–1.066)
High1591 1 (reference)
Hypertension
No3642 1 (reference)
Yes51070.19771.029 (0.985–1.075)
Diabetes
No7260 1 (reference)
Yes1489<0.0011.181 (1.116–1.249)
Metabolic syndrome
No6209 1 (reference)
Yes25400.35781.022 (0.976–1.071)

3.3. Analysis of the HNC Risk by Sex According to Each Factor

The effect of each factor on the risk of HNC was analyzed by subgrouping men and women. Multivariable analysis was adjusted for factors including age and smoking and alcohol drinking status. The underweight group had a significantly increased aHR in both men and women (1.710 (95% CI, 1.506–1.942) and 1.578 (95% CI, 1.155–2.156), respectively). However, the pre-obese and obese groups had a decreased aHR only in men (0.804 (95% CI, 0.759–0.852) and 0.778 (95% CI, 0.736–0.822)). That is, a high BMI did not influence HNC in women. Central obesity also affected HNC only in men. For central obesity, the aHR decreased to 0.937 (95% CI, 0.889–0.988) in men. Similarly, high TC and high LDL cholesterol levels were the factors that decreased the aHR to 0.918 (95% CI, 0.876–0.962) and 0.830 (95% CI, 0.792–0.870) only in men. The TG and HDL cholesterol levels were not associated with HNC in either men or women. Although hypertension had no relationship with HNC when men and women were considered together, it increased the aHR to 1.049 (95% CI, 1.001–1.101) only in the male group when men and women were considered separately. Both subgroups showed significance regarding the risk of diabetes. The aHRs of diabetes were 1.183 (95% CI, 1.114–1.256) and 1.190 (95% CI, 1.016–1.939) in men and women, respectively (Table 3).
Table 3

Hazard ratio of head and neck cancer risk by sex according to each factor.

Parameter n Male (n = 7308) n Female (n = 1441)
p ValueHR (95% CI)p ValueHR (95% CI)
BMI, kg/m2
<18.5260<00011.710 (1.506–1.942)430.00421.578 (1.155–2.156)
18.5–22.92751< 1 (reference)499 1 (reference)
23–24.91951<0001 5060.15461.101 (0.964–1.258)
≥252346<0001 3930.43241.052 (0.928–1.192)
Central obesity
No5435 1 (reference)1256 1 (reference)
Yes18730.0160.937 (0.889–0.988)1850.6841.033 (0.883–1.208)
Total cholesterol
Low4458 1 (reference)740 1 (reference)
High28500.00040.918 (0.876–0.962)7010.25190.941 (0.847–1.044)
LDL cholesterol
Low2862 1 (reference)395 1 (reference)
High4446<00010.830 (0.792–0.870)10460.25880.935 (0.833–1.05)
TG
Low4622 1 (reference)1035 1 (reference)
High26860.2281.03 (0.982–1.08)4060.83231.013 (0.901–1.138)
HDL cholesterol
Low6201 1 (reference)957 1 (reference)
High11070.82541.007 (0.945–1.074)4840.60070.971 (0.87–1.084)
Hypertension
No2942 1 (reference)700 1 (reference)
Yes43660.04671.049 (1.001–1.101)7410.60070.971 (0.87–1.084)
Diabetes
No6001 1 (reference)1259 1 (reference)
Yes1307<00011.183 (1.114–1.256)1820.03071.190 (1.016–1.393)

4. Discussion

Metabolic syndrome is diagnosed with metabolic diseases such as central obesity, glucose intolerance, hypertension, and dyslipidemia. Metabolic syndrome is increasing in various countries, including developed countries, as diabetes and obesity are increasing [22,23]. It is well known that metabolic syndrome affects various diseases, but recent reports have shown that metabolic syndrome increases the risk of various cancers. Previous studies have reported that metabolic syndrome increases the risk of developing and recurring liver, colorectal, bladder, endometrial, pancreatic, and breast cancers [24,25,26,27,28]. However, there have been few studies on the relationship between metabolic syndrome and head and neck cancer. Thus, this study aimed to investigate the association between metabolic syndrome and HNC. However, in our study, metabolic syndrome did not increase the risk of HNC, as in other cancers. This is consistent with a recent cohort study that reported no correlation between metabolic syndrome and head and neck cancer [29]. Our study results show that the components of metabolic syndrome had different effects on HNC. Some components had positive effects, while others had inverse effects. Therefore, we investigated the correlation between each component of metabolic syndrome and the risk of HNC. This study investigated the effects of metabolic diseases, such as dyslipidemia, obesity, hypertension, and diabetes, on HNC using big data from the KNHIS. In general, obesity and dyslipidemia are risk factors for many diseases, but these are not associated with HNC. In high BMI or central obesity, the risk of HNC decreased. Low TC and low LDL cholesterol levels were also risk factors for HNC. However, these only affected men and not women. Diabetes was a risk factor for HNC in both men and women, and hypertension was a risk factor only in men. In addition, as already known, we confirmed that age, smoking, and alcohol drinking were significant risk factors for HNC. There have been many studies on the association between lipids and various cancers. Previous studies have shown different views. According to one study, high cholesterol levels increased the risk of prostate cancer, and cholesterol-lowering drugs, such as statins, help prevent prostate cancer [30]. Another study also reported that the use of statins reduced the risk of lung, colorectal, prostate, and bladder cancers and melanoma, suggesting that high cholesterol levels increase the risk of various cancers [31]. They suggested that cholesterol affects the production and inhibition of cancer-related molecules. A similar study reported that high TG levels increased the risk of colorectal cancer, explaining that TG attenuates insulin resistance [25]. A meta-analysis reported that HDL cholesterol and TC had an inverse correlation with lung cancer but TG had a positive correlation. They suggested that this was because lipid metabolism may act as a special mechanism in the etiology of lung cancer [15]. As such, there is disagreement as to whether the blood lipid level is a risk factor for various cancers, and the exact mechanism of how lipids affect the development of cancer is not yet known. However, since lipids are directly or indirectly involved in cell cycle-related metabolism, such as apoptosis and inflammation [32,33,34,35], they may also affect the pathogenesis of cancer. In our study, low TC and LDL cholesterol levels increased the risk of HNC, and the TG and HDL cholesterol levels did not affect the incidence of HNC. Further research is needed to determine whether this is due to the specialty of HNC, various confounding factors, biological differences between men and women, or differences in lifestyles such as smoking and drinking between men and women. Reverse causation was also considered. A study suggested that patients with HNC have poor nutritional intake due to dysphagia and loss of appetite [36]. HNC is much more common in men, and it is possible that the blood lipid levels were lowered due to HNC rather than the HNC risk increased due to low lipid levels. Obesity is known to be closely related to the metabolism of glucose and lipids and has a great influence on hormones [37]. It has been reported that obesity is associated with various cancers. An extensive study showed that obesity increases the risk of various cancers such as colorectal, breast, endometrial, kidney, esophageal, pancreatic, and gastric cancers. This study shows that obesity destroys the balance of hormones and causes metabolic disorders, which increases the risk of cancer [13]. However, the mechanism by which obesity increases the risk of cancer remains unclear. There are still many disagreements regarding the effect of obesity on the development of HNC. Several cohort studies have reported that HNC is not associated with obesity [36,38] and several studies have reported that a high BMI lowers the incidence of HNC [39,40,41]. Other studies have reported that abdominal obesity increases the risk of HNC [40,42]. It has also been reported that lean people have a poor prognosis for HNC. This is because obesity acts as a buffer in the treatment of HNC, which has protective effects against cachexia, malnourishment, and immune compromise caused by dysphagia and poor appetite, which slows the growth of HNC and inhibits metastasis [17]. If obesity itself makes HNC grow slowly and inhibit metastasis, it may be suggested that obesity has the effect of preventing HNC. In our study, abdominal obesity and high BMI lowered the risk of HNC only in men. This result has not been presented in previous studies. As mentioned earlier, the reasons for this result have not been demonstrated, but possible reasons can be considered by examining previous studies. First, as seen in our study, men smoke and drink more than women, and many carcinogens from cigarettes damage DNA [43]. It is possible that this molecular mechanism is related to body weight. Lean people have more DNA damage from smoking, which has a greater impact on the development of HNC [44]. Conversely, smoking causes hormonal changes and dietary habits, destroys muscles, and causes low weight [45,46]. Therefore, men smoke much more than women, and because of this, the number of lean people also increases, thereby increasing the incidence of HNC. Second, the incidence of HNC is high because of the high smoking rate among men. Before the diagnosis of HNC, symptoms such as dysphagia and odynophagia could cause low weight. Therefore, it can be seen that low weight increases the incidence of HNC as a confounding effect [47]. Many studies have shown that diabetes increases the incidence of almost all cancers. It seems obvious that diabetes is a risk factor for many types of cancer. A previous study explained that diabetes increases cancer risk through hyperinsulinemia, hyperglycemia, and chronic inflammation. This study demonstrated the mechanisms by which these factors influence cancer and suggested that the control of diabetes helps inhibit the development of cancer [10]. Another cohort study reported that diabetes increases the risk of HNC [48]. This is consistent with our findings. However, another large study reported that diabetes and metabolic syndrome each lowered the risk of head and neck cancer. Further molecular studies, as well as well-controlled demographic studies are needed to elucidate the relationship between diabetes and head and neck cancer [49]. In the case of hypertension, there is controversy. A cohort study conducted in various countries reported a correlation between hypertension and the risk of various cancers. They showed that hypertension also increased cancer mortality [12]. Other studies have suggested a correlation between hypertension and cancer, but some studies have suggested that there is no correlation [50,51]. In addition, to our knowledge, no study has demonstrated a clear mechanism of the effect of hypertension on various cancers. In our study, hypertension was a risk factor for HNC only in men. Smoking and alcohol consumption are risk factors for both hypertension and HNC; therefore, our finding may be due to the high smoking rate and high alcohol consumption in men. Recent studies have shown that a large number of patients with head and neck cancer have comorbidities and complications. The most common comorbidities were hypertension, metastatic cancer, and lung disease, and the most common complications included hemorrhage/hematoma and postoperative pulmonary function decline. Since the rate of head and neck cancer in the elderly is high, the management of comorbidities and complications will be important [52]. Our study is meaningful as it is the first cohort study of the relationship between HNC and metabolic diseases using nationwide big data. In addition, this study was conducted by subgrouping men and women, and it was possible to closely examine the effects of metabolic diseases on HNC. This can help identify the unique characteristics of HNC that are different from those of other cancers.

5. Conclusions

Metabolic syndrome itself had no effect on the incidence of HNC, but a different finding was noted when each metabolic disease constituting metabolic syndrome was studied separately. Obesity, which is generally evaluated as BMI and central obesity, lowered the risk of HNC in men. Underweight was a strong risk factor for HNC in both men and women. High LDL cholesterol and TC levels had protective effects on HNC in men, but not in women. Diabetes increased the risk of HNC in both men and women, whereas hypertension increased the risk of HNC only in men. Further studies are needed to evaluate the effects of metabolic diseases on HNC.
  51 in total

Review 1.  Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms.

Authors:  Eugenia E Calle; Rudolf Kaaks
Journal:  Nat Rev Cancer       Date:  2004-08       Impact factor: 60.716

2.  Cohort Profile: The National Health Insurance Service-National Sample Cohort (NHIS-NSC), South Korea.

Authors:  Juneyoung Lee; Ji Sung Lee; Sook-Hee Park; Soon Ae Shin; KeeWhan Kim
Journal:  Int J Epidemiol       Date:  2017-04-01       Impact factor: 7.196

3.  New AHA and ACC guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk.

Authors:  Gerald Klose; Frank Ulrich Beil; Hans Dieplinger; Arnold von Eckardstein; Bernhard Föger; Ioanna Gouni-Berthold; Franz Heigl; Wolfgang Koenig; Gert M Kostner; Ulf Landmesser; Ulrich Laufs; Frank Leistikow; Winfried März; Georg Noll; Klaus G Parhofer; Bernhard Paulweber; Walter F Riesen; Jürgen R Schaefer; Elisabeth Steinhagen-Thiessen; Armin Steinmetz; Hermann Toplak; Christoph Wanner; Eberhard Windler
Journal:  Wien Klin Wochenschr       Date:  2014-03-11       Impact factor: 1.704

4.  Prevalence of the metabolic syndrome and overweight among adults in China.

Authors:  Dongfeng Gu; Kristi Reynolds; Xigui Wu; Jing Chen; Xiufang Duan; Robert F Reynolds; Paul K Whelton; Jiang He
Journal:  Lancet       Date:  2005 Apr 16-22       Impact factor: 79.321

5.  Metabolic syndrome as a prognostic factor for breast cancer recurrences.

Authors:  Patrizia Pasanisi; Franco Berrino; Michela De Petris; Elisabetta Venturelli; Antonio Mastroianni; Salvatore Panico
Journal:  Int J Cancer       Date:  2006-07-01       Impact factor: 7.396

6.  Cigarette smoking and fat distribution in 21,828 British men and women: a population-based study.

Authors:  Dexter Canoy; Nicholas Wareham; Robert Luben; Ailsa Welch; Sheila Bingham; Nicholas Day; Kay-Tee Khaw
Journal:  Obes Res       Date:  2005-08

7.  A prospective cohort study of body size and risk of head and neck cancers in the NIH-AARP diet and health study.

Authors:  Arash Etemadi; Mark G O'Doherty; Neal D Freedman; Albert R Hollenbeck; Sanford M Dawsey; Christian C Abnet
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-08-29       Impact factor: 4.254

8.  The association between statins and cancer incidence in a veterans population.

Authors:  Wildon R Farwell; Richard E Scranton; Elizabeth V Lawler; Robert A Lew; Mary T Brophy; Louis D Fiore; J Michael Gaziano
Journal:  J Natl Cancer Inst       Date:  2008-01-08       Impact factor: 13.506

9.  The effect of metabolic syndrome on head and neck cancer incidence risk: a population-based prospective cohort study.

Authors:  Huaili Jiang; Lei Zhou; Qiangsheng He; Kanglun Jiang; Jinqiu Yuan; Xinsheng Huang
Journal:  Cancer Metab       Date:  2021-06-03

10.  Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study.

Authors:  Christina Fitzmaurice; Degu Abate; Naghmeh Abbasi; Hedayat Abbastabar; Foad Abd-Allah; Omar Abdel-Rahman; Ahmed Abdelalim; Amir Abdoli; Ibrahim Abdollahpour; Abdishakur S M Abdulle; Nebiyu Dereje Abebe; Haftom Niguse Abraha; Laith Jamal Abu-Raddad; Ahmed Abualhasan; Isaac Akinkunmi Adedeji; Shailesh M Advani; Mohsen Afarideh; Mahdi Afshari; Mohammad Aghaali; Dominic Agius; Sutapa Agrawal; Ayat Ahmadi; Elham Ahmadian; Ehsan Ahmadpour; Muktar Beshir Ahmed; Mohammad Esmaeil Akbari; Tomi Akinyemiju; Ziyad Al-Aly; Assim M AlAbdulKader; Fares Alahdab; Tahiya Alam; Genet Melak Alamene; Birhan Tamene T Alemnew; Kefyalew Addis Alene; Cyrus Alinia; Vahid Alipour; Syed Mohamed Aljunid; Fatemeh Allah Bakeshei; Majid Abdulrahman Hamad Almadi; Amir Almasi-Hashiani; Ubai Alsharif; Shirina Alsowaidi; Nelson Alvis-Guzman; Erfan Amini; Saeed Amini; Yaw Ampem Amoako; Zohreh Anbari; Nahla Hamed Anber; Catalina Liliana Andrei; Mina Anjomshoa; Fereshteh Ansari; Ansariadi Ansariadi; Seth Christopher Yaw Appiah; Morteza Arab-Zozani; Jalal Arabloo; Zohreh Arefi; Olatunde Aremu; Habtamu Abera Areri; Al Artaman; Hamid Asayesh; Ephrem Tsegay Asfaw; Alebachew Fasil Ashagre; Reza Assadi; Bahar Ataeinia; Hagos Tasew Atalay; Zerihun Ataro; Suleman Atique; Marcel Ausloos; Leticia Avila-Burgos; Euripide F G A Avokpaho; Ashish Awasthi; Nefsu Awoke; Beatriz Paulina Ayala Quintanilla; Martin Amogre Ayanore; Henok Tadesse Ayele; Ebrahim Babaee; Umar Bacha; Alaa Badawi; Mojtaba Bagherzadeh; Eleni Bagli; Senthilkumar Balakrishnan; Abbas Balouchi; Till Winfried Bärnighausen; Robert J Battista; Masoud Behzadifar; Meysam Behzadifar; Bayu Begashaw Bekele; Yared Belete Belay; Yaschilal Muche Belayneh; Kathleen Kim Sachiko Berfield; Adugnaw Berhane; Eduardo Bernabe; Mircea Beuran; Nickhill Bhakta; Krittika Bhattacharyya; Belete Biadgo; Ali Bijani; Muhammad Shahdaat Bin Sayeed; Charles Birungi; Catherine Bisignano; Helen Bitew; Tone Bjørge; Archie Bleyer; Kassawmar Angaw Bogale; Hunduma Amensisa Bojia; Antonio M Borzì; Cristina Bosetti; Ibrahim R Bou-Orm; Hermann Brenner; Jerry D Brewer; Andrey Nikolaevich Briko; Nikolay Ivanovich Briko; Maria Teresa Bustamante-Teixeira; Zahid A Butt; Giulia Carreras; Juan J Carrero; Félix Carvalho; Clara Castro; Franz Castro; Ferrán Catalá-López; Ester Cerin; Yazan Chaiah; Wagaye Fentahun Chanie; Vijay Kumar Chattu; Pankaj Chaturvedi; Neelima Singh Chauhan; Mohammad Chehrazi; Peggy Pei-Chia Chiang; Tesfaye Yitna Chichiabellu; Onyema Greg Chido-Amajuoyi; Odgerel Chimed-Ochir; Jee-Young J Choi; Devasahayam J Christopher; Dinh-Toi Chu; Maria-Magdalena Constantin; Vera M Costa; Emanuele Crocetti; Christopher Stephen Crowe; Maria Paula Curado; Saad M A Dahlawi; Giovanni Damiani; Amira Hamed Darwish; Ahmad Daryani; José das Neves; Feleke Mekonnen Demeke; Asmamaw Bizuneh Demis; Birhanu Wondimeneh Demissie; Gebre Teklemariam Demoz; Edgar Denova-Gutiérrez; Afshin Derakhshani; Kalkidan Solomon Deribe; Rupak Desai; Beruk Berhanu Desalegn; Melaku Desta; Subhojit Dey; Samath Dhamminda Dharmaratne; Meghnath Dhimal; Daniel Diaz; Mesfin Tadese Tadese Dinberu; Shirin Djalalinia; David Teye Doku; Thomas M Drake; Manisha Dubey; Eleonora Dubljanin; Eyasu Ejeta Duken; Hedyeh Ebrahimi; Andem Effiong; Aziz Eftekhari; Iman El Sayed; Maysaa El Sayed Zaki; Shaimaa I El-Jaafary; Ziad El-Khatib; Demelash Abewa Elemineh; Hajer Elkout; Richard G Ellenbogen; Aisha Elsharkawy; Mohammad Hassan Emamian; Daniel Adane Endalew; Aman Yesuf Endries; Babak Eshrati; Ibtihal Fadhil; Vahid Fallah Omrani; Mahbobeh Faramarzi; Mahdieh Abbasalizad Farhangi; Andrea Farioli; Farshad Farzadfar; Netsanet Fentahun; Eduarda Fernandes; Garumma Tolu Feyissa; Irina Filip; Florian Fischer; James L Fisher; Lisa M Force; Masoud Foroutan; Marisa Freitas; Takeshi Fukumoto; Neal D Futran; Silvano Gallus; Fortune Gbetoho Gankpe; Reta Tsegaye Gayesa; Tsegaye Tewelde Gebrehiwot; Gebreamlak Gebremedhn Gebremeskel; Getnet Azeze Gedefaw; Belayneh K Gelaw; Birhanu Geta; Sefonias Getachew; Kebede Embaye Gezae; Mansour Ghafourifard; Alireza Ghajar; Ahmad Ghashghaee; Asadollah Gholamian; Paramjit Singh Gill; Themba T G Ginindza; Alem Girmay; Muluken Gizaw; Ricardo Santiago Gomez; Sameer Vali Gopalani; Giuseppe Gorini; Bárbara Niegia Garcia Goulart; Ayman Grada; Maximiliano Ribeiro Guerra; Andre Luiz Sena Guimaraes; Prakash C Gupta; Rahul Gupta; Kishor Hadkhale; Arvin Haj-Mirzaian; Arya Haj-Mirzaian; Randah R Hamadeh; Samer Hamidi; Lolemo Kelbiso Hanfore; Josep Maria Haro; Milad Hasankhani; Amir Hasanzadeh; Hamid Yimam Hassen; Roderick J Hay; Simon I Hay; Andualem Henok; Nathaniel J Henry; Claudiu Herteliu; Hagos D Hidru; Chi Linh Hoang; Michael K Hole; Praveen Hoogar; Nobuyuki Horita; H Dean Hosgood; Mostafa Hosseini; Mehdi Hosseinzadeh; Mihaela Hostiuc; Sorin Hostiuc; Mowafa Househ; Mohammedaman Mama Hussen; Bogdan Ileanu; Milena D Ilic; Kaire Innos; Seyed Sina Naghibi Irvani; Kufre Robert Iseh; Sheikh Mohammed Shariful Islam; Farhad Islami; Nader Jafari Balalami; Morteza Jafarinia; Leila Jahangiry; Mohammad Ali Jahani; Nader Jahanmehr; Mihajlo Jakovljevic; Spencer L James; Mehdi Javanbakht; Sudha Jayaraman; Sun Ha Jee; Ensiyeh Jenabi; Ravi Prakash Jha; Jost B Jonas; Jitendra Jonnagaddala; Tamas Joo; Suresh Banayya Jungari; Mikk Jürisson; Ali Kabir; Farin Kamangar; André Karch; Narges Karimi; Ansar Karimian; Amir Kasaeian; Gebremicheal Gebreslassie Kasahun; Belete Kassa; Tesfaye Dessale Kassa; Mesfin Wudu Kassaw; Anil Kaul; Peter Njenga Keiyoro; Abraham Getachew Kelbore; Amene Abebe Kerbo; Yousef Saleh Khader; Maryam Khalilarjmandi; Ejaz Ahmad Khan; Gulfaraz Khan; Young-Ho Khang; Khaled Khatab; Amir Khater; Maryam Khayamzadeh; Maryam Khazaee-Pool; Salman Khazaei; Abdullah T Khoja; Mohammad Hossein Khosravi; Jagdish Khubchandani; Neda Kianipour; Daniel Kim; Yun Jin Kim; Adnan Kisa; Sezer Kisa; Katarzyna Kissimova-Skarbek; Hamidreza Komaki; Ai Koyanagi; Kristopher J Krohn; Burcu Kucuk Bicer; Nuworza Kugbey; Vivek Kumar; Desmond Kuupiel; Carlo La Vecchia; Deepesh P Lad; Eyasu Alem Lake; Ayenew Molla Lakew; Dharmesh Kumar Lal; Faris Hasan Lami; Qing Lan; Savita Lasrado; Paolo Lauriola; Jeffrey V Lazarus; James Leigh; Cheru Tesema Leshargie; Yu Liao; Miteku Andualem Limenih; Stefan Listl; Alan D Lopez; Platon D Lopukhov; Raimundas Lunevicius; Mohammed Madadin; Sameh Magdeldin; Hassan Magdy Abd El Razek; Azeem Majeed; Afshin Maleki; Reza Malekzadeh; Ali Manafi; Navid Manafi; Wondimu Ayele Manamo; Morteza Mansourian; Mohammad Ali Mansournia; Lorenzo Giovanni Mantovani; Saman Maroufizadeh; Santi Martini S Martini; Tivani Phosa Mashamba-Thompson; Benjamin Ballard Massenburg; Motswadi Titus Maswabi; Manu Raj Mathur; Colm McAlinden; Martin McKee; Hailemariam Abiy Alemu Meheretu; Ravi Mehrotra; Varshil Mehta; Toni Meier; Yohannes A Melaku; Gebrekiros Gebremichael Meles; Hagazi Gebre Meles; Addisu Melese; Mulugeta Melku; Peter T N Memiah; Walter Mendoza; Ritesh G Menezes; Shahin Merat; Tuomo J Meretoja; Tomislav Mestrovic; Bartosz Miazgowski; Tomasz Miazgowski; Kebadnew Mulatu M Mihretie; Ted R Miller; Edward J Mills; Seyed Mostafa Mir; Hamed Mirzaei; Hamid Reza Mirzaei; Rashmi Mishra; Babak Moazen; Dara K Mohammad; Karzan Abdulmuhsin Mohammad; Yousef Mohammad; Aso Mohammad Darwesh; Abolfazl Mohammadbeigi; Hiwa Mohammadi; Moslem Mohammadi; Mahdi Mohammadian; Abdollah Mohammadian-Hafshejani; Milad Mohammadoo-Khorasani; Reza Mohammadpourhodki; Ammas Siraj Mohammed; Jemal Abdu Mohammed; Shafiu Mohammed; Farnam Mohebi; Ali H Mokdad; Lorenzo Monasta; Yoshan Moodley; Mahmood Moosazadeh; Maryam Moossavi; Ghobad Moradi; Mohammad Moradi-Joo; Maziar Moradi-Lakeh; Farhad Moradpour; Lidia Morawska; Joana Morgado-da-Costa; Naho Morisaki; Shane Douglas Morrison; Abbas Mosapour; Seyyed Meysam Mousavi; Achenef Asmamaw Muche; Oumer Sada S Muhammed; Jonah Musa; Ashraf F Nabhan; Mehdi Naderi; Ahamarshan Jayaraman Nagarajan; Gabriele Nagel; Azin Nahvijou; Gurudatta Naik; Farid Najafi; Luigi Naldi; Hae Sung Nam; Naser Nasiri; Javad Nazari; Ionut Negoi; Subas Neupane; Polly A Newcomb; Haruna Asura Nggada; Josephine W Ngunjiri; Cuong Tat Nguyen; Leila Nikniaz; Dina Nur Anggraini Ningrum; Yirga Legesse Nirayo; Molly R Nixon; Chukwudi A Nnaji; Marzieh Nojomi; Shirin Nosratnejad; Malihe Nourollahpour Shiadeh; Mohammed Suleiman Obsa; Richard Ofori-Asenso; Felix Akpojene Ogbo; In-Hwan Oh; Andrew T Olagunju; Tinuke O Olagunju; Mojisola Morenike Oluwasanu; Abidemi E Omonisi; Obinna E Onwujekwe; Anu Mary Oommen; Eyal Oren; Doris D V Ortega-Altamirano; Erika Ota; Stanislav S Otstavnov; Mayowa Ojo Owolabi; Mahesh P A; Jagadish Rao Padubidri; Smita Pakhale; Amir H Pakpour; Adrian Pana; Eun-Kee Park; Hadi Parsian; Tahereh Pashaei; Shanti Patel; Snehal T Patil; Alyssa Pennini; David M Pereira; Cristiano Piccinelli; Julian David Pillay; Majid Pirestani; Farhad Pishgar; Maarten J Postma; Hadi Pourjafar; Farshad Pourmalek; Akram Pourshams; Swayam Prakash; Narayan Prasad; Mostafa Qorbani; Mohammad Rabiee; Navid Rabiee; Amir Radfar; Alireza Rafiei; Fakher Rahim; Mahdi Rahimi; Muhammad Aziz Rahman; Fatemeh Rajati; Saleem M Rana; Samira Raoofi; Goura Kishor Rath; David Laith Rawaf; Salman Rawaf; Robert C Reiner; Andre M N Renzaho; Nima Rezaei; Aziz Rezapour; Ana Isabel Ribeiro; Daniela Ribeiro; Luca Ronfani; Elias Merdassa Roro; Gholamreza Roshandel; Ali Rostami; Ragy Safwat Saad; Parisa Sabbagh; Siamak Sabour; Basema Saddik; Saeid Safiri; Amirhossein Sahebkar; Mohammad Reza Salahshoor; Farkhonde Salehi; Hosni Salem; Marwa Rashad Salem; Hamideh Salimzadeh; Joshua A Salomon; Abdallah M Samy; Juan Sanabria; Milena M Santric Milicevic; Benn Sartorius; Arash Sarveazad; Brijesh Sathian; Maheswar Satpathy; Miloje Savic; Monika Sawhney; Mehdi Sayyah; Ione J C Schneider; Ben Schöttker; Mario Sekerija; Sadaf G Sepanlou; Masood Sepehrimanesh; Seyedmojtaba Seyedmousavi; Faramarz Shaahmadi; Hosein Shabaninejad; Mohammad Shahbaz; Masood Ali Shaikh; Amir Shamshirian; Morteza Shamsizadeh; Heidar Sharafi; Zeinab Sharafi; Mehdi Sharif; Ali Sharifi; Hamid Sharifi; Rajesh Sharma; Aziz Sheikh; Reza Shirkoohi; Sharvari Rahul Shukla; Si Si; Soraya Siabani; Diego Augusto Santos Silva; Dayane Gabriele Alves Silveira; Ambrish Singh; Jasvinder A Singh; Solomon Sisay; Freddy Sitas; Eugène Sobngwi; Moslem Soofi; Joan B Soriano; Vasiliki Stathopoulou; Mu'awiyyah Babale Sufiyan; Rafael Tabarés-Seisdedos; Takahiro Tabuchi; Ken Takahashi; Omid Reza Tamtaji; Mohammed Rasoul Tarawneh; Segen Gebremeskel Tassew; Parvaneh Taymoori; Arash Tehrani-Banihashemi; Mohamad-Hani Temsah; Omar Temsah; Berhe Etsay Tesfay; Fisaha Haile Tesfay; Manaye Yihune Teshale; Gizachew Assefa Tessema; Subash Thapa; Kenean Getaneh Tlaye; Roman Topor-Madry; Marcos Roberto Tovani-Palone; Eugenio Traini; Bach Xuan Tran; Khanh Bao Tran; Afewerki Gebremeskel Tsadik; Irfan Ullah; Olalekan A Uthman; Marco Vacante; Maryam Vaezi; Patricia Varona Pérez; Yousef Veisani; Simone Vidale; Francesco S Violante; Vasily Vlassov; Stein Emil Vollset; Theo Vos; Kia Vosoughi; Giang Thu Vu; Isidora S Vujcic; Henry Wabinga; Tesfahun Mulatu Wachamo; Fasil Shiferaw Wagnew; Yasir Waheed; Fitsum Weldegebreal; Girmay Teklay Weldesamuel; Tissa Wijeratne; Dawit Zewdu Wondafrash; Tewodros Eshete Wonde; Adam Belay Wondmieneh; Hailemariam Mekonnen Workie; Rajaram Yadav; Abbas Yadegar; Ali Yadollahpour; Mehdi Yaseri; Vahid Yazdi-Feyzabadi; Alex Yeshaneh; Mohammed Ahmed Yimam; Ebrahim M Yimer; Engida Yisma; Naohiro Yonemoto; Mustafa Z Younis; Bahman Yousefi; Mahmoud Yousefifard; Chuanhua Yu; Erfan Zabeh; Vesna Zadnik; Telma Zahirian Moghadam; Zoubida Zaidi; Mohammad Zamani; Hamed Zandian; Alireza Zangeneh; Leila Zaki; Kazem Zendehdel; Zerihun Menlkalew Zenebe; Taye Abuhay Zewale; Arash Ziapour; Sanjay Zodpey; Christopher J L Murray
Journal:  JAMA Oncol       Date:  2019-12-01       Impact factor: 31.777

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.